Leading in the agentic era: How to put people first as you adopt AI agents
cloud.google.com·2h ago
AI Engineering
MIT Technology Review·Jun 9·5 min read
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
TL;DR
A gap exists in effective anti-aging treatments that can significantly reverse biological age. David Sinclair plans to test an oral 'reprogramming' drug in human trials as part of the XPrize competition.
✦ Why It Matters
Engineers and researchers can explore new avenues in drug development focused on aging and cellular reprogramming.
Key Takeaways
- Monitor developments in Sinclair's oral drug trials for potential breakthroughs.
- Explore existing supplements that may contribute to longevity.
- Stay informed about the XPrize competition's progress and finalists.
- Engage with ongoing discussions about age measurement standards in research.
How It Works
The proposed drug utilizes epigenetic reprogramming, which involves resetting the molecular controls on DNA, known as epigenetic marks. These marks influence a cell's metabolism and identity, potentially allowing for rejuvenation across various body systems.